Aa
AASLD 2014: Tenofovir Continues to Work Well Against Hepatitis B Virus for 8 Years
Thoughts? My thought it that will this drug is good, they need to speed up the cure instead of focusing on trying to "pimp" this drug.
http://www.hivandhepatitis.com/hepatitis-b/hepatitis-b-topics/hbv-treatment/4948-aasld-2014-tenofovir-continues-to-work-well-against-hepatitis-b-virus-for-8-years
Most chronic hepatitis B patients treated with tenofovir (Viread) for 8 years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.Serological response rates continued to increase over time and kidney and bone-related side effects remained uncommon.
Nucleoside/nucleotide analog antivirals such as tenofovir, entecavir (Baraclude), adefovir (Hepsera), and lamivudine (Epivir) are the mainstay of chronic hepatitis B treatment. Although they can effectively suppress hepatitis B virus (HBV) replication while on therapy, they typically do not eradicate the virus and therefore may need to be taken long term. Viral suppression has been shown to improve liver fibrosis and reduce the risk of complications such as liver cancer.
Patrick Marcellin from Hôpital Beaujonin Paris and colleagues presented the latest findings from Gilead Sciences' Study 102 and Study 103, a pair of Phase 3 trials evaluating tenofovir in hepatitis B "e" antigen (HBeAg) negative and HBeAg positive patients, respectively.
Together, the studies enrolled more than 600 participants, most previously untreated. Nearly three-quarters were men, about 60% were white, about 30% were Asian, the mean age was approximately 40 years, and 24% had liver cirrhosis. A majority of HBeAg negative participants (64%) had HBV genotype D, with 11% having genotypes A, B, and C; genotypes were more evenly distributed in the HBeAg positive study.
Participants in both trials were randomly assigned to receive 300 mg tenofovir or 10 mg adefovir for 48 weeks, after which they could elect to continue on open-label tenofovir. People with continued detectable HBV DNA while on tenofovir had the option of adding emtricitabine (Emtriva) at week 72 or later. Safety and efficacy were assessed every 3 months, resistance testing was performed annually, and DEXA bone mineral density scans were performed starting at year 4 of follow-up.
About 90% of participants completed the initial blinded 48-week phase and entered the open-label phase. A total of 266 HBeAg negative patients (71% of those initially randomized and treated) and 146 HBeAg positive patients (55%) completed follow-up through week 384, or approximately 8 years -- the originally planned study duration.
Results
75% of HBeAg negative participants and 58% of HBeAg positive patients had viral suppression (HBV DNA <69 IU/mL) at year 8 in an intent-to-treat analysis.
In an as-treated or observed analysis of those who stayed on treatment, the corresponding rates were 99% and 98%, respectively.
1.1% of HBeAg negative participants and 13% of HBeAg positive patients experienced hepatitis B surface antigen (HBsAg) loss, while 0.7% and 10%, respectively, achieved HBsAg seroconversion.
In a multivariate analysis, predictors of HBsAg loss included white race/ethnicity, HBV genotype A or D, being infected for 4 years or less, and a lower baseline HBsAg level.
In the HBeAg positive study, 32% of patients experienced HBeAg loss and 21% achieved HBeAg seroconversion.
In a subset of 90 patients evaluated at 165 time points over 8 years, there was no evidence of tenofovir resistance.
Tenofovir remained generally safe and well-tolerated throughout the course of follow-up.
There were 7 (1.2%) drug-related serious adverse events and 13 (2.2%) adverse events leading to treatment discontinuation during the open-label phase.
20 patients (3.4%) reduced their doses or interrupted or discontinued treatment due to kidney-related adverse events including elevated creatinine (2.2%), elevated phosphate (1.7%), and reduced creatinine clearance to <50 mL/min (1.0%).
2.0% and 3.1% of patients developed osteopenia (low bone mineral density) at the hip and spine, respectively; 1.2% and 1.9% progressed from osteopenia to more severe osteoporosis, but none went from normal bone density to osteoporosis.
Conversely, 2.0% and 4.4% improved from osteopenia to normal bone density at the hip and spine, respectively; 0.8% and 1.1% improved from osteoporosis to osteopenia.
A total of 34 bone fractures occurred in 31 patients (5.3%), but these were mostly due to trauma rather than bone loss.
Over an 8-year period of treatment with tenofovir, "virologic and serologic responses were durable" and viral suppression was "consistently maintained," the researchers concluded.
"Renal events were uncommon," they added, and there was "no clinically relevant bone loss over 4-year follow-up."
Another study presented at the meeting found that adding pegylated interferon to tenofovir increased the likelihood of HBsAg loss.
http://www.hivandhepatitis.com/hepatitis-b/hepatitis-b-topics/hbv-treatment/4948-aasld-2014-tenofovir-continues-to-work-well-against-hepatitis-b-virus-for-8-years
Most chronic hepatitis B patients treated with tenofovir (Viread) for 8 years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.Serological response rates continued to increase over time and kidney and bone-related side effects remained uncommon.
Nucleoside/nucleotide analog antivirals such as tenofovir, entecavir (Baraclude), adefovir (Hepsera), and lamivudine (Epivir) are the mainstay of chronic hepatitis B treatment. Although they can effectively suppress hepatitis B virus (HBV) replication while on therapy, they typically do not eradicate the virus and therefore may need to be taken long term. Viral suppression has been shown to improve liver fibrosis and reduce the risk of complications such as liver cancer.
Patrick Marcellin from Hôpital Beaujonin Paris and colleagues presented the latest findings from Gilead Sciences' Study 102 and Study 103, a pair of Phase 3 trials evaluating tenofovir in hepatitis B "e" antigen (HBeAg) negative and HBeAg positive patients, respectively.
Together, the studies enrolled more than 600 participants, most previously untreated. Nearly three-quarters were men, about 60% were white, about 30% were Asian, the mean age was approximately 40 years, and 24% had liver cirrhosis. A majority of HBeAg negative participants (64%) had HBV genotype D, with 11% having genotypes A, B, and C; genotypes were more evenly distributed in the HBeAg positive study.
Participants in both trials were randomly assigned to receive 300 mg tenofovir or 10 mg adefovir for 48 weeks, after which they could elect to continue on open-label tenofovir. People with continued detectable HBV DNA while on tenofovir had the option of adding emtricitabine (Emtriva) at week 72 or later. Safety and efficacy were assessed every 3 months, resistance testing was performed annually, and DEXA bone mineral density scans were performed starting at year 4 of follow-up.
About 90% of participants completed the initial blinded 48-week phase and entered the open-label phase. A total of 266 HBeAg negative patients (71% of those initially randomized and treated) and 146 HBeAg positive patients (55%) completed follow-up through week 384, or approximately 8 years -- the originally planned study duration.
Results
75% of HBeAg negative participants and 58% of HBeAg positive patients had viral suppression (HBV DNA <69 IU/mL) at year 8 in an intent-to-treat analysis.
In an as-treated or observed analysis of those who stayed on treatment, the corresponding rates were 99% and 98%, respectively.
1.1% of HBeAg negative participants and 13% of HBeAg positive patients experienced hepatitis B surface antigen (HBsAg) loss, while 0.7% and 10%, respectively, achieved HBsAg seroconversion.
In a multivariate analysis, predictors of HBsAg loss included white race/ethnicity, HBV genotype A or D, being infected for 4 years or less, and a lower baseline HBsAg level.
In the HBeAg positive study, 32% of patients experienced HBeAg loss and 21% achieved HBeAg seroconversion.
In a subset of 90 patients evaluated at 165 time points over 8 years, there was no evidence of tenofovir resistance.
Tenofovir remained generally safe and well-tolerated throughout the course of follow-up.
There were 7 (1.2%) drug-related serious adverse events and 13 (2.2%) adverse events leading to treatment discontinuation during the open-label phase.
20 patients (3.4%) reduced their doses or interrupted or discontinued treatment due to kidney-related adverse events including elevated creatinine (2.2%), elevated phosphate (1.7%), and reduced creatinine clearance to <50 mL/min (1.0%).
2.0% and 3.1% of patients developed osteopenia (low bone mineral density) at the hip and spine, respectively; 1.2% and 1.9% progressed from osteopenia to more severe osteoporosis, but none went from normal bone density to osteoporosis.
Conversely, 2.0% and 4.4% improved from osteopenia to normal bone density at the hip and spine, respectively; 0.8% and 1.1% improved from osteoporosis to osteopenia.
A total of 34 bone fractures occurred in 31 patients (5.3%), but these were mostly due to trauma rather than bone loss.
Over an 8-year period of treatment with tenofovir, "virologic and serologic responses were durable" and viral suppression was "consistently maintained," the researchers concluded.
"Renal events were uncommon," they added, and there was "no clinically relevant bone loss over 4-year follow-up."
Another study presented at the meeting found that adding pegylated interferon to tenofovir increased the likelihood of HBsAg loss.
yes for correcting bone loss it is all right, mk7 vit k2 is also in natto in high quantities if you like its taste
I am no doctor, so any advice that I give you on here is not a doctor's advice. I only took reccommendations and will give some on what made me feel better. Vitamin K2 helps support bone mass and strength.
Stef can correct me if I am wrong, but I believe it is 1,000mcg of Vitamin K2 (w/ MK-7) for every 5,000iu of Vitamin D3 you take.
Stef can correct me if I am wrong, but I believe it is 1,000mcg of Vitamin K2 (w/ MK-7) for every 5,000iu of Vitamin D3 you take.
Hi Mel, I'll answer. How am I now? A *lot* better than how I was this time last year. I seriously felt like I was on my death bed when my Hepatitis B went active (I'm still convinced it's an acute case taking longer than usual to clear too btw)
Is there any way to know about these complications? Yes, they warn you about these issues before you start the medication. They are common side effects of Tenofovir. Some say no bone density loss happens with Hep B patients but I have proved otherwise (see my DXEA scan in clincal trial results thread I made)
We get monitored every month. I think the point of the trial is that doctors are trying to figure out how to avoid these issues. I am not sure on the dose I am taking, because it's a double blinded study. Means I am taking either one or the other. According to this, though, I already have Viral Supression since my Viral Load is now 54.
I have done things to help though! Mostly, upping my Vitamin D3 to 20,000iu a day (Doctors only wanted me to do 5,000iu -- thanks to Stef for convincing me others, he's been a blessing!) and my Vitamin K2 (Again, thanks Stef!). I do find it funny that they brought patient 102 and 103 to the board. I missed that boat by 1 as I am patient "101" on the trial.
Is there any way to know about these complications? Yes, they warn you about these issues before you start the medication. They are common side effects of Tenofovir. Some say no bone density loss happens with Hep B patients but I have proved otherwise (see my DXEA scan in clincal trial results thread I made)
We get monitored every month. I think the point of the trial is that doctors are trying to figure out how to avoid these issues. I am not sure on the dose I am taking, because it's a double blinded study. Means I am taking either one or the other. According to this, though, I already have Viral Supression since my Viral Load is now 54.
I have done things to help though! Mostly, upping my Vitamin D3 to 20,000iu a day (Doctors only wanted me to do 5,000iu -- thanks to Stef for convincing me others, he's been a blessing!) and my Vitamin K2 (Again, thanks Stef!). I do find it funny that they brought patient 102 and 103 to the board. I missed that boat by 1 as I am patient "101" on the trial.
how are you know ? still taking but a lower dose ? isn't any way to know before that you are going to have this complications ?i mean if you do regular blood tests, can you manage to avoid this ?
I've seen these 2 happen to me within the 7 months I have taken this drug:
20 patients (3.4%) reduced their doses or interrupted or discontinued treatment due to kidney-related adverse events including elevated creatinine (2.2%), elevated phosphate (1.7%), and reduced creatinine clearance to <50 mL/min (1.0%).
2.0% and 3.1% of patients developed osteopenia (low bone mineral density) at the hip and spine, respectively; 1.2% and 1.9% progressed from osteopenia to more severe osteoporosis, but none went from normal bone density to osteoporosis.
No idea how to reverse it
20 patients (3.4%) reduced their doses or interrupted or discontinued treatment due to kidney-related adverse events including elevated creatinine (2.2%), elevated phosphate (1.7%), and reduced creatinine clearance to <50 mL/min (1.0%).
2.0% and 3.1% of patients developed osteopenia (low bone mineral density) at the hip and spine, respectively; 1.2% and 1.9% progressed from osteopenia to more severe osteoporosis, but none went from normal bone density to osteoporosis.
No idea how to reverse it
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
